Global monitoring of antiviral resistance
in currently circulating human influenza viruses, November 2011.
in influenza may not only emerge during treatment but also sometimes transmit widely to replace wild-type strains in the absence of drug pressure.
mutations and genotype associated amino acid substitutions in treatment-naive hepatitis B virus-infected individuals from the Indian subcontinent Intervirology.
and the future landscape of hepatitis C virus infection therapy.
Prolonged influenza virus shedding and emergence of antiviral resistance
in immunocompromised patients and ferrets.
Counterfeits pose a significant threat to patients, their communities and global public health--by driving antibiotic and antiviral resistance
. For example, a substandard dose of a medication is potentially more dangerous than a dose with no active ingredient because it could spur a disease mutation and resistance to a drug.
Apparent ease "The apparent ease with which antiviral resistance
emerges in A/H7N9 viruses is concerning," wrote the study authors -- insisting that early treatment remained the best course of action.
Assays for antiviral resistance
marker detection have been developed.
The development of new antiviral agents for influenza is receiving much greater attention because of the frequent emergence of antiviral resistance
during oseltamivir, its association with clinical failure in immuno-compromised hosts, and the emergence of new pandemic subtypes of influenza A virus (Beigel and Bray 2008; Hayden 2001; lson et al.
From influenza viruses (Virological surveillance and antiviral resistance
of human influenza virus in Argentina, 2005-2008) to HIV (Prevalence and patterns of HIV transmitted drug resistance in Guatemala and HIV transmitted drug resistance in adult and pediatric populations in Panama), different examples are presented on the prevalence of resistance to antiviral drugs.
Knowledge of the locally prevalent influenza strains as well as local patterns of antiviral resistance
should inform that judgment.
BOSTON--The forthcoming availability of the protease inhibitors telaprevir and boceprevir for the treatment of chronic hepatitis C is likely to vastly improve virologic response rates and cut treatment times, but experts warn that such advancements need to be balanced against the "huge potential" for misuse of the agents and the need to manage side effects and monitor for antiviral resistance